(GTBP) GT Biopharma, Inc. Business Model Canvas Research

GT Biopharma, Inc. relies on CDMO and manufacturing partners to make recombinant proteins, run GMP production, handle fill-finish, and complete release testing for clinical supply. For a clinical-stage biologics pipeline, these partners also help scale batches fast enough to support ongoing studies and reduce supply risk.

• GMP production for trial material
• Fill-finish and quality testing support
• Scale-up for ongoing studies

GT Biopharma, Inc. uses regulatory and clinical development advisors to guide IND filings, protocol amendments, and safety reporting, where FDA rules can require serious adverse event updates within 7 to 15 days. These advisors help keep hematology and oncology programs aligned with FDA expectations, which matters in a field where the U.S. FDA approved 55 novel drugs in 2024.

• IND and amendment support
• Safety reporting deadlines
• FDA-facing trial strategy
• Hematology and oncology focus

External experts also help shape trial design so GT Biopharma, Inc. can move faster with fewer regulatory gaps, especially when study plans change during development.

GT Biopharma, Inc.'s key activity for GTB-5550 is preclinical advancement of a B7-H3-targeted asset for solid tumors. This program broadens the pipeline beyond hematologic cancers, and preclinical characterization must confirm activity, safety, and dosing before any clinical entry.

• Targets B7-H3 positive solid tumors
• Expands beyond blood cancer focus
• Needs preclinical validation before trials

GT Biopharma, Inc. must keep regulatory filings, chemistry, manufacturing, and controls aligned so its clinical programs stay IND-ready and investor-capital efficient. In biotech, only about 10% of drug candidates reach approval, and CMC gaps can slow timelines fast, so partnering and licensing work also matters to share cost, access expertise, and fund trials.

• File and maintain IND/CMC packages
• Control quality, supply, and scale-up
• Secure partners for cash and reach

GTB-3650 and GTB-5550 give GT Biopharma, Inc. two preclinical shots on goal beyond its core platform, extending coverage into myeloid leukemia and solid tumors. That broader base matters because earlier-stage oncology assets can create optionality before clinical readouts, but they also raise the need for disciplined capital use.

• Two preclinical assets
• Myeloid leukemia focus
• Solid tumor expansion
• Broader pipeline optionality

GT Biopharma, Inc. depends on clinical and regulatory expertise to run oncology trials, handle biologics development, and keep safety and compliance on track. In immuno-oncology, where programs can stall without strong regulatory operations, this know-how helps move candidates through preclinical work, IND filing, and early-stage testing faster and with fewer errors.

• Specialized trial staff reduces development delays.
• Regulatory know-how supports safer filings.
• Immuno-oncology expertise helps advance programs.

GT Biopharma, Inc. has 1 clinical candidate and 2 preclinical assets, so it can capture near-term readouts while keeping longer-term shots on goal. That staged mix supports a lower-burn innovation path versus an all-clinical pipeline and gives the company multiple value-creation points as programs move from preclinical work into human testing.

• 1 clinical candidate for near-term data
• 2 preclinical assets for pipeline depth
• Staged model spreads development risk

GT Biopharma, Inc.’s partner-ready licensing value sits in its licensed IP and early proof-of-concept data, which can make the platform and pipeline relevant to oncology partners. In biotech, these deals often monetize through co-development and out-licensing, where upfront cash, milestones, and royalties can come before full commercialization.

• Licensed IP supports deal leverage
• Proof-of-concept data lowers partner risk
• Out-licensing can bring upfront cash

GT Biopharma, Inc. needs close ties with IP licensors and future partners because technology transfer turns licensed assets into clinical and commercial rights. In the latest filings, the Company still has no marketed product, so moving know-how, data, and manufacturing steps cleanly is key to value creation.

• Keep licensor ties active
• Secure transfer rights early
• Support clinic-to-market handoff

These relationships help reduce delays in development, protect rights, and speed partner deals. For a pre-revenue biotech, that can matter as much as the science itself.

As a public clinical-stage biotech, GT Biopharma, Inc. must keep investors updated on trial progress, pipeline moves, and financing needs through SEC filings and corporate updates. For a company with no approved product revenue, capital markets support and clear cash-runway messaging are central to shareholder trust.

• Trial updates drive the story.
• Financing plans shape investor confidence.
• Capital access is critical.

GT Biopharma, Inc. uses public-market communication to fund R&D, so earnings updates, SEC filings, and investor presentations are core channels. These updates help keep investors informed and support access to equity capital, which is critical for a clinical-stage biotech with limited product revenue.

• SEC filings
• Earnings updates
• Investor presentations

If GT Biopharma, Inc. wins approval, its biologic therapy would likely flow through hospital and specialty oncology sites, where hematology-oncology physicians write most orders. Access will hinge on formulary approval and reimbursement; in the U.S., Medicare covered about 67 million people in 2025, so payer rules can shape uptake fast.

• Hospital and specialty oncology channels first
• Hematology-oncology physicians drive prescribing
• Formulary and reimbursement decide access

Academic hospitals and specialty cancer centers are GT Biopharma, Inc.’s core trial sites, because they already handle complex biologics, infusion monitoring, and high-acuity patients. In 2025, U.S. cancer care demand stayed huge, with about 2.0 million new cancer cases expected and National Cancer Institute funding above $7 billion, so these centers remain the key access point for study enrollment and future adoption.

• Complex biologics need monitored dosing
• Academic centers drive trial enrollment
• Research hospitals speed clinical validation

Strategic biopharma partners are a key customer segment for GT Biopharma, Inc. because other drug makers may want its immuno-oncology assets for co-development or licensing, creating non-dilutive cash flow before any broad launch. This fits a model where partnership fees, milestones, and royalties can help fund R&D while keeping dilution lower.

• Targets companies seeking immuno-oncology assets
• Supports co-development and licensing deals
• Can bring non-dilutive value before launch

General and administrative overhead for GT Biopharma, Inc. covers payroll, finance, legal, and corporate governance tied to public-company reporting. Based in Brisbane, California, these costs fund day-to-day execution and help keep the listing, controls, and compliance work moving.

This line item is usually one of the main cash uses for a development-stage biotech, so tighter control here matters for runway.

• Payroll and finance support
• Legal and governance compliance
• Brisbane, California headquarters
• Daily operating execution

GT Biopharma, Inc. must keep licensed rights in force, defend its patent position, and fund FDA and legal filings, so IP, licensing, and regulatory spend stays a recurring cash need. In a tech-led oncology business, these costs are core to keeping the pipeline, data room, and commercialization path alive.

• License upkeep protects product rights
• Patents defend the science moat
• Regulatory and legal work adds fixed overhead

GT Biopharma, Inc. is a clinical-stage biotech, so research grants and other non-dilutive funding can support early oncology work without adding share dilution. This cash often funds platform research and translational studies while the Company advances high-risk programs before any product revenue exists.

• Funds early R&D
• Avoids equity dilution
• Supports translational work
• Fits high-risk biotech

GT Biopharma, Inc. is still a development-stage, pre-revenue company, so equity financing is its main cash source before commercialization. Proceeds from stock sales and other capital raises fund R and D, clinical trials, and day-to-day operations, which means dilution risk stays high until product sales begin.

• Primary cash source before revenue
• Funds R and D and trials
• Supports operating cash needs
• High dilution risk for holders